Summary & Overview
HCPCS J3350: Injection of Urea, Up to 40 gm
HCPCS Level II code J3350 denotes administration of urea, up to 40 grams, as an injectable therapeutic agent. Nationally, this code captures billing for urea injections used in specific dermatologic and other clinical indications where topical or systemic urea formulations are indicated but injectable administration is required. Accurate coding of J3350 matters for service classification, claims processing, and tracking utilization of this medication.
Key payers addressed in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise briefing on payer coverage patterns, common modifiers in use, and contextual clinical considerations tied to injectable urea therapy. The publication also outlines benchmarks for claim submission, common sites of service where J3350 is billed, and policy considerations that affect reimbursement and prior authorization practices.
This summary provides clinicians, billing professionals, and policy analysts a focused reference on coding, expected service settings, and payer landscape for J3350. Data not available in the input is noted where applicable, and the report avoids clinical recommendations while highlighting areas for administrative attention such as documentation and correct code use.
Billing Code Overview
HCPCS Level II code J3350 represents an injection of urea, up to 40 gm. This code describes the healthcare service of administering a urea preparation by injection for therapeutic use.
-
Service type: Medication administration (injectable therapeutic agent)
-
Typical site of service: Ambulatory care settings such as physician offices, outpatient clinics, and hospital outpatient departments where injectable medications are administered.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with focal areas of hyperkeratosis, callus formation, or thickened nails requiring debridement and softening prior to definitive treatment. A podiatrist, dermatologist, or wound care clinician evaluates the patient in an outpatient clinic or ambulatory surgery center. After assessment, the clinician decides to apply a topical keratolytic agent for chemical debridement. The service involves preparation of the treatment area, application of J3350 (injection, urea, up to 40 gm) when the formulation and route align with a billed injectable urea product, observation for local reaction, and documentation of dosage, lot number, and site. Typical workflow steps: history and focused exam, informed consent, preparation and aseptic technique, administration of the product, post-application instructions, and follow-up visit scheduling. The usual site of service is an outpatient clinic, physician office, podiatry office, or ambulatory surgery center.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Standard reporting when no circumstances apply |
22 | Increased procedural services |